1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Isocitrate Dehydrogenase (IDH)

Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producingalpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate(a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as themitochondrion and peroxisome.

Isocitrate Dehydrogenase (IDH) Related Products (18):

Cat. No. Product Name Effect Purity
  • HY-18767
    Ivosidenib Inhibitor 99.24%
    Ivosidenib (AG-120) is a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor with an IC50 of 12 nM for mouse IDH1R132H.
  • HY-18690
    Enasidenib Inhibitor 99.95%
    Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.
  • HY-18082
    AGI-5198 Inhibitor 99.99%
    AGI-5198 is a potent and selective mutant IDH1R132H inhibitor with an IC50 of 0.07 μM.
  • HY-104042
    Vorasidenib Inhibitor 99.87%
    Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor, which exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG) with IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K.
  • HY-15734
    AGI-6780 Inhibitor 98.87%
    AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2WT with IC50 of 190±8.1 nM.
  • HY-107977
    IDH1 Inhibitor 3 Inhibitor
    IDH1 Inhibitor 3 (compound 6f) is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor, with an IC50 of 45 nM for IDH1R132H.
  • HY-114459
    Mutant IDH1-IN-4 Inhibitor >99.0%
    Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.
  • HY-128661
    IDH1 Inhibitor 2 Inhibitor
    IDH1 Inhibitor 2 is a potent IDH1 inhibitor via a direct covalent modification of His315, with an IC50 of 110 nM.
  • HY-104036
    IDH-305 Inhibitor 98.01%
    IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT)).
  • HY-19540
    GSK864 Inhibitor 99.36%
    GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
  • HY-100020
    BAY-1436032 Inhibitor 98.94%
    BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
  • HY-18690A
    Enasidenib mesylate Inhibitor 99.25%
    Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
  • HY-18767A
    (R,S)-Ivosidenib Inhibitor 98.61%
    (R,S)-Ivosidenib is a inhibitor of Isocitrate Dehydrogenase (IDH1).
  • HY-12475
    Mutant IDH1-IN-1 Inhibitor 99.60%
    Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
  • HY-13972
    Mutant IDH1 inhibitor Inhibitor 98.69%
    Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
  • HY-18717
    Mutant IDH1-IN-2 Inhibitor
    Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
  • HY-114226
    Olutasidenib Inhibitor 98.35%
    Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1) that could be used in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • HY-112601
    IDH1 Inhibitor 1 Inhibitor
    IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant IDH1 inhibitor with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM for IDH1R132H, IDH1R132C, and IDH1WT, respectively. Anticancer activity.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.